Brief: Jaguar Health Reports Phase 3 Ontarget Trial Results For Crofelemer
23/07/2024 13:10
July 23 (Reuters) - Jaguar Health Inc JAGX.O :
* JAGUAR HEALTH REPORTS PHASE 3 ONTARGET TRIAL RESULTS FOR
ITS
CANCER SUPPORTIVE CARE DRUG CROFELEMER
* JAGUAR HEALTH - INITIAL RESULTS FROM ONTARGET STUDY SHOW
THAT
MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PIVOTAL CLINICAL
TRIAL DID NOT MEET PRIMARY ENDPOINT
Source text for Eikon: ID:n0001104659-24-081721
Further company coverage: JAGX.O
((Reuters.Briefs@thomsonreuters.com;))